Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
FASN-IN-1
Cat. No.:
OB0225LY-0028
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR.
Size:
Product Overview
Description:
FASN-IN-1 is a small molecule compound that inhibits fatty acid synthase (FASN) and reduces fatty acid synthesis, thereby affecting cellular energy metabolism.
Synonym:
TVB-2460; 1808260-84-5; (2S)-N-[4-[4-(Diethylsulfamoyl)phenyl]-1,3-thiazol-2-yl]-2-methylbutanamide
CAS No.:
1808260-84-5
Compound CID:
118356203
Formula:
C18H25N3O3S2
Formula Weight:
395.54
Specification
Relative Density:
1.240 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
FASN-IN-1 is mainly used in obesity-related cancer research, especially in certain cancer cell types that depend on fatty acid synthesis. Its inhibitory effects may also be important in the treatment of metabolic syndrome and obesity-related diseases.
Library Information
Targets:
Fatty acid synthase
Receptors:
Fatty acid synthase
Pathways:
Metabolism
Plate Number:
AOCL-1
Plate Location:
c9
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
100 mg/mL; 252.82 mM
